What is the 13F Pro Quality Score for MYGN?

13F Pro ranks MYRIAD GENETICS INC (MYGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MYGN's current score at https://13fpro.ai/company/MYGN (free sign-up required for the full ranking).

Which hedge funds own the most MYGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MYGN include BlackRock,, MILLENNIUM MANAGEMENT, Vestal Point Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MYGN as soon as new 13F filings post.

Where does 13F Pro source MYGN data?

All MYRIAD GENETICS INC fundamentals and ownership data come directly from SEC EDGAR. MYRIAD GENETICS INC files with the SEC under CIK 899923. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MYGN in?

MYRIAD GENETICS INC (MYGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives MYGN's revenue?

Per MYRIAD GENETICS INC's latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: Cancer Care Continuum ($114.1M, -10.6% YoY); Mental Health ($36.8M, -2.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MYGN.

What are MYGN's largest expenses?

MYRIAD GENETICS INC's latest 10-Q reports these as the largest expense items: Sales and marketing expense ($83.1M, +15.6% YoY); Cost of revenue ($63.7M, +3.9% YoY); Research and development expense ($25.0M, -2.3% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is MYGN research updated on 13F Pro?

MYGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MYRIAD GENETICS INC(MYGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 899923 MYGN stock profile & AI dashboard →

13F Pro Quality Score

24.4/100

Rank #2,699 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

27.1/100

Profitability

9.8/100

Balance Sheet

3.4/100

Earnings Quality

44.5/100

Free Cash Flow

18.9/100

Institutional Flow

2.9/100

Revenue Scale

46.2/100

Dilution Risk

27.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MYGN Scores 24/100

exact factor attribution · 2026-09-11

MYGN's composite is held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

-0.6 pts

45th pct

Scale

-0.6 pts

46th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.1 pts

27th pct

Institutional flow

-2.4 pts

3th pct

Revenue growth

-4.6 pts

27th pct

Capital efficiency

-4.7 pts

3th pct

Free cash flow

-4.7 pts

19th pct

Profitability

-6.0 pts

10th pct

Latest change (2026-07-31): 30 → 33 · ↑ Profit margin 10→19; ↑ Free cash flow 27→38; despite ↓ Revenue growth 46→32

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MYGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MYRIAD GENETICS INC (MYGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MYGN at 24.4/100 on a 32-signal composite quality model, placing it at rank #2,699 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (2.9) and balance sheet strength (3.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MYRIAD GENETICS INC reports quarterly revenue of $190.7M, net income of $-43.2M. Top institutional holders of MYGN by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, Vestal Point Capital, based on the most recent SEC filings. MYGN trades on the Nasdaq exchange and files with the SEC under CIK 899923. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MYGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MYRIAD GENETICS INC directly from SEC EDGAR. MYRIAD GENETICS INC's 13F Pro composite quality score has ranged between 18 and 33 since 2021, currently 24.4 — an improving long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about MYRIAD GENETICS INC

Quirks, history, and lore behind MYGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. molecular diagnostics company · small-cap · listed on Nasdaq · headquartered in Utah.
2
The Numbers
Annual revenue in the range of $700–800 million, driven almost entirely by genetic testing services billed to insurers and patients.
3
The History
Founded in the early 1990s, it built its business around pioneering hereditary cancer risk testing at a time when sequencing a gene was still a scientific novelty.
4
The Secret
The company once held patents on the BRCA1 and BRCA2 genes — the breast-cancer risk genes — giving it a near-monopoly on testing, until the Supreme Court struck the patents down in 2013.
5
The Lore
Angelina Jolie's 2013 op-ed about her preventive double mastectomy — triggered by a BRCA test result — sent a wave of women into genetic counseling and put this company's core product on front pages worldwide.
6
The Giveaway
Its flagship test, myRisk Hereditary Cancer, and its ticker symbol that literally contains the word "MY" — this Salt Lake City genetics lab has your DNA destiny in its name.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving MYGN's Business? Latest 10-Q Breakdown

AI-extracted from MYRIAD GENETICS INC's 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue declined 10.5% YoY to $190.7M, driven by reimbursement headwinds across all segments and $11M in prior-period revenue adjustments, while operating losses narrowed to $38.9M.

Biggest Revenue Drivers

Cancer Care Continuum$114.1M-10.6% YoY

15% decrease in revenue per test due to declines in reimbursement, partially offset by 6% volume increase

Mental Health$36.8M-2.6% YoY

4% increase in volume, offset by 6% decrease in revenue per test from unfavorable estimates on aged orders

Biggest Revenue Drivers

Total revenue: $190.7M-10.5% YoY

Cancer Care Continuum$114.1M-10.6% YoY

15% decrease in revenue per test due to declines in reimbursement, partially offset by 6% volume increase

Mental Health$36.8M-2.6% YoY

4% increase in volume, offset by 6% decrease in revenue per test from unfavorable estimates on aged orders

Largest Expense Items

Sales and marketing expense$83.1M+15.6% YoY

$5.0M increase in personnel-related costs and $4.2M increase in marketing and sales expenses

Cost of revenue$63.7M+3.9% YoY

Increased fulfillment costs and personnel-related expenses

Research and development expense$25.0M-2.3% YoY

Relatively consistent with prior year period

Watch Items from the Filing

Revenue concentration in three segments: Cancer Care 60%, Prenatal Health 21%, Mental Health 19%; reimbursement declines persist across all lines, with $11M in Q2 revenue adjustments for prior-period estimates.
Goodwill and intangible asset impairment charges: $4.5M recorded in Q1 2026 for Women's Health reporting unit, reducing goodwill to zero; remaining goodwill of $47.1M ($29.8M Mental Health, $17.3M International) faces ongoing pressure.
Debt covenant compliance: $125M term loan outstanding bears 10.1% interest; minimum revenue covenant of $615M (Dec 2025) increases to $974M by Dec 2029; company was in compliance as of June 30, 2026.
Qui tam litigation unsealed January 2025; court denied motion to dismiss on July 9, 2026, except for one count; no material accrual recorded; litigation remains ongoing with uncertain outcome.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$190.7M

Net Income

Q2 2026

$-43.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Total Assets

-5.7% YoY

$638.9MFY 2026

FY23 $1.19BFY24 $1.09BFY25 $677.3MFY26 $638.9M

Total Debt

+103.2% YoY

$120.7MFY 2026

FY23 $38.4MFY24 $38.8MFY25 $59.4MFY26 $120.7M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	$638.9M -5.7%	$677.3M -37.6%	$1.09B -8.6%	$1.19B -1.9%	$1.21B -11.0%	$1.36B
Total Debt	$120.7M +103.2%	$59.4M +53.1%	$38.8M +1.0%	$38.4M	$0.00 -100.0%	$208.2M

Get alerted when MYGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MYRIAD GENETICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MYGN

BlackRock, Inc.
$62.2M10,890,440 sh
MILLENNIUM MANAGEMENT LLC
$37.8M6,620,372 sh
Vestal Point Capital, LP
$32.7M5,735,000 sh
STATE STREET CORP
$28.5M4,985,060 sh
D. E. Shaw & Co., Inc.
$26.2M4,582,083 sh
VANGUARD CAPITAL MANAGEMENT LLC
$23.3M4,081,376 sh
ACADIAN ASSET MANAGEMENT LLC
$17.8M3,126,973 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$17.6M3,079,670 sh
AQR CAPITAL MANAGEMENT LLC
$15.8M2,766,689 sh
MORGAN STANLEY
$14.2M2,481,104 sh

Fund	Value	Shares
BlackRock, Inc.	$62.2M	10,890,440
MILLENNIUM MANAGEMENT LLC	$37.8M	6,620,372
Vestal Point Capital, LP	$32.7M	5,735,000
STATE STREET CORP	$28.5M	4,985,060
D. E. Shaw & Co., Inc.	$26.2M	4,582,083
VANGUARD CAPITAL MANAGEMENT LLC	$23.3M	4,081,376
ACADIAN ASSET MANAGEMENT LLC	$17.8M	3,126,973
VANGUARD PORTFOLIO MANAGEMENT LLC	$17.6M	3,079,670
AQR CAPITAL MANAGEMENT LLC	$15.8M	2,766,689
MORGAN STANLEY	$14.2M	2,481,104

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MYGN on your watchlist

Track score changes the day MYRIAD GENETICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MYGN a good stock to buy?

13F Pro's AI-powered analysis of MYRIAD GENETICS INC (MYGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MYGN are available on the MYGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MYGN is classified as a small company.

Which hedge funds own MYGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MYGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MYRIAD GENETICS INC's investment landscape.